$0.07
+0.02 (+31.40%)
Open$0.06
Previous Close$0.06
Day High$0.08
Day Low$0.05
52W High$0.77
52W Low$0.03
Volume—
Avg Volume12.19M
Market Cap18.64M
P/E Ratio—
EPS$-0.38
SectorBiotechnology
Analyst Ratings
Buy
11 analysts
Price Target
+26,989.5% upside
Current
$0.07
$0.07
Target
$20.29
$20.29
$11.90
$20.29 avg
$29.33
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 35.15M | 49.62M | 23.70M |
| Net Income | -109,194,702 | -138,748,033 | -3,056,252 |
| Profit Margin | -310.8% | -295.3% | -12.9% |
| EBITDA | -104,191,708 | -139,746,043 | -4,785,189 |
| Free Cash Flow | — | — | -2,136,953 |
| Rev Growth | -29.2% | -29.2% | +16.7% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $261.07 | +3.99% | 126.9 | 461.26B |
| AMGN | Amgen Inc | $374.15 | +3.55% | 25.9 | 201.93B |
| GILD | Gilead Sciences Inc | $131.27 | +4.21% | 17.7 | 162.98B |
| VRTX | Vertex Pharmaceuticals Inc | $528.04 | +6.03% | 30.4 | 131.79B |
| REGN | Regeneron Pharmaceuticals | $654.27 | +4.73% | 15.5 | 68.59B |
| ALNY | Alnylam Pharmaceuticals Inc | $312.78 | +3.68% | 72.4 | 41.76B |